HACKENSACK MERIDIAN HEALTH
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2016-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
98
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (79 trials with phase data)• Click on a phase to view related trials
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 70
- Registration Number
- NCT07011342
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Speech-derived Digital Biomarkers Study
- Conditions
- Mild Cognitive Impairment (MCI)Alzheimer Disease
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 100
- Registration Number
- NCT06994767
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
OBWELL: Innovative Psychotherapeutic Intervention to Treat Postpartum Depression
- Conditions
- Post Partum Depression
- First Posted Date
- 2025-05-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 72
- Registration Number
- NCT06991166
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
- Conditions
- Monoclonal Gammopathy of Uncertain SignificanceSmoldering Myeloma
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 67
- Registration Number
- NCT06987708
Transitions of Care Clinic (TOCC)
- Conditions
- Heart Failure With Preserved Ejection Fraction
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 150
- Registration Number
- NCT06937827
- Locations
- 🇺🇸
Ocean University Medical Center, Brick, New Jersey, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 20
- Next
News
New Cancer Center at JFK University Medical Center Aims to Enhance Multidisciplinary Care
Hackensack Meridian Health opened a new cancer center at JFK University Medical Center in Edison, NJ in May 2025, bringing together multiple oncology specialties under one roof.
New Jersey Transforms Cancer Care Landscape with First Freestanding Cancer Hospital
RWJBarnabas Health and Rutgers Cancer Institute have opened the Jack & Sheryl Morris Cancer Center in New Brunswick, marking New Jersey's first freestanding comprehensive cancer hospital.
Cancer Vaccines Emerge as Promising Frontier in Oncology with Multiple Approaches Showing Clinical Success
• Cancer vaccines are gaining momentum across multiple tumor types, with FDA-approved options like BCG, sipuleucel-T, and talimogene laherparepvec demonstrating clinical utility in bladder cancer, prostate cancer, and melanoma respectively. • Novel vaccine approaches including mRNA-based mRNA-4157, KRAS-targeted ELI-002, and viral vector-based aglatimagene besadenovec are showing promising results in clinical trials, with significant improvements in survival outcomes across various cancers. • Experts believe cancer vaccines hold particular promise in early-stage and high-risk disease settings by targeting micrometastatic disease, potentially increasing cure rates and transforming treatment paradigms when combined with existing immunotherapies.
Phase 1 Trial Shows Promise for Novel Intraperitoneal Therapy in Peritoneal Metastases
A phase 1 dose-escalation trial evaluating PIPAC-MMC combined with systemic chemotherapy demonstrated manageable safety profile in patients with appendiceal and colorectal peritoneal metastases.